VALENTINA HOYOS to Humans
This is a "connection" page, showing publications VALENTINA HOYOS has written about Humans.
Connection Strength
0.203
-
ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer. Mol Ther. 2025 Apr 02; 33(4):1621-1641.
Score: 0.025
-
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024 03; 26(3):266-275.
Score: 0.023
-
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol. 2022; 13:835762.
Score: 0.020
-
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11).
Score: 0.020
-
Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone. Cancer Med. 2021 07; 10(14):4790-4795.
Score: 0.019
-
The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood. 2016 09 29; 128(13):1679-87.
Score: 0.014
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.013
-
Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica. 2012 Nov; 97(11):1622-31.
Score: 0.010
-
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
Score: 0.009
-
Pan-cancer proteogenomics expands the landscape of therapeutic targets. Cell. 2024 Aug 08; 187(16):4389-4407.e15.
Score: 0.006
-
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024 04 25; 143(17):1726-1737.
Score: 0.006
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
Score: 0.005
-
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 05 05; 29(5):1808-1820.
Score: 0.005
-
CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer. 2018 05 10; 6(1):34.
Score: 0.004
-
3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus. Biomaterials. 2016 Apr; 84:76-85.
Score: 0.003
-
An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85.
Score: 0.003
-
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015 May; 21(5):524-9.
Score: 0.003
-
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482.
Score: 0.003
-
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res. 2014 Feb 15; 20(4):962-71.
Score: 0.003
-
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood. 2011 May 05; 117(18):4736-45.
Score: 0.002
-
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. Blood. 2011 Mar 24; 117(12):3353-62.
Score: 0.002
-
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009 Sep 15; 15(18):5852-60.
Score: 0.002
-
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8.
Score: 0.002
-
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008 Sep 01; 112(5):1876-85.
Score: 0.002